# Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants

> **NCT00937521** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 1507 (actual)

## Conditions studied

- Meningococcal Meningitis
- Meningococcal Infections

## Interventions

- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Meningococcal B vaccine
- **BIOLOGICAL:** Control
- **BIOLOGICAL:** Meningococcal B vaccine with antipyretic

## Key facts

- **NCT ID:** NCT00937521
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2010-11
- **Final completion:** 2012-02
- **Target enrollment:** 1507 (ACTUAL)
- **Last updated:** 2015-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937521, "Safety and Immunogenicity in Dose-Ranging and Formulation-Finding Meningococcal B (MenB) Vaccine Study in 2-month-old Infants". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00937521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*